<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747877</url>
  </required_header>
  <id_info>
    <org_study_id>LCC-HM05/7287</org_study_id>
    <secondary_id>CDR0000612567</secondary_id>
    <secondary_id>EU-20873</secondary_id>
    <secondary_id>ISRCTN60123120</secondary_id>
    <secondary_id>EudraCT-2006-005890-24</secondary_id>
    <nct_id>NCT00747877</nct_id>
  </id_info>
  <brief_title>High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy</brief_title>
  <official_title>Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leeds Cancer Centre at St. James's University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and bortezomib before a peripheral stem cell transplant stops
      the growth of cancer cells by stopping them from dividing or killing them. Giving
      colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells
      move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is
      then given to prepare the bone marrow for the stem cell transplant. The stem cells are then
      returned to the patient to replace the blood-forming cells that were destroyed by the
      chemotherapy and bortezomib. It is not yet known whether high-dose melphalan given together
      with a second stem cell transplant is more effective than low-dose cyclophosphamide in
      treating patients with relapsed multiple myeloma.

      PURPOSE: This randomized phase III trial is studying giving high-dose melphalan together with
      a second stem cell transplant to see how well it works compared with low-dose
      cyclophosphamide in treating patients with relapsed multiple myeloma after chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the effect on freedom from disease progression in patients with relapsed
           multiple myeloma treated with re-induction therapy comprising bortezomib, doxorubicin
           hydrochloride, and dexamethasone (PAD) followed by a second autologous stem cell
           transplantation (ASCT) with high-dose melphalan vs low-dose cyclophosphamide
           consolidation therapy.

      Secondary

        -  To assess the response rate of PAD in patients following a previous autograft.

        -  To compare the overall response rate of patients following high-dose melphalan
           chemotherapy and autologous stem cell transplantation with low-dose cyclophosphamide
           consolidation therapy.

        -  To assess the overall survival of patients treated with this regimen.

        -  To assess the safety and toxicity of a second ASCT in these patients.

        -  To assess the safety and toxicity of PAD in these patients.

        -  To assess the feasibility of stem cell collection following PAD in these patients.

        -  To determine the impact of this regimen on pain and quality of life in these patients.

      OUTLINE: This is a multicenter study.

        -  Re-induction (PAD) therapy: Patients receive bortezomib IV on days 1, 4, 8, and 11,
           doxorubicin hydrochloride IV continuously on days 1-4, and oral dexamethasone on days
           1-4 (and days 8-11 and 15-18 of course 1 only). Treatment repeats every 21 days for up
           to 4 courses in the absence of disease progression or unacceptable toxicity.

        -  Peripheral blood stem cell (PBSC) mobilization and harvest: Within 6-12 weeks, some
           patients receive cyclophosphamide IV on day 0 and filgrastim (G-CSF) subcutaneously (SC)
           beginning on day 1 and continuing to time of PBSC harvest. PBSCs are then collected.

      Patients who successfully complete re-induction therapy and have adequate PBSC mobilization
      are stratified according to length of first remission or plateau (≤ vs ≥ 24 months) and
      response to PAD re-induction therapy (stable disease vs ≥ partial response). Patients are
      randomized to 1 of 2 arms.

        -  Arm I (high-dose melphalan consolidation therapy): Patients receive high-dose melphalan
           IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.

        -  Arm II (low-dose cyclophosphamide consolidation therapy): Patients receive low-dose
           cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.

      Patients complete the EORTC QLQ-C30 and EORTC QLQ-MY20, the Brief Pain Inventory Short Form
      (BPI-SF), and the Leeds Assessment of Neuropathic Symptoms and Signs (Self Assessment) Pain
      Scale (S-LANSS) questionnaires at baseline and after completion of re-induction therapy.

      Patients are followed monthly for up to 100 days after ASCT or at 30 days after low-dose
      cyclophosphamide and then every 3 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to disease progression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate to bortezomib, doxorubicin hydrochloride, and dexamethasone (PAD)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate following randomized treatments</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and safety of autologous stem cell transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and safety of weekly cyclophosphamide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and safety of PAD therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of stem cell collection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high-dose melphalan IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low-dose cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Patients undergo autologous hematopoietic stem cell transplantation on day 0.</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of relapsed multiple myeloma

               -  Symptomatic disease, including non-secretory

          -  Previously treated with standard chemotherapy and autologous stem cell transplantation

          -  Requires therapy for first progressive disease AND at least 18 months since first stem
             cell transplantation

               -  Patients who were previously immunofixation-negative and are now
                  immunofixation-positive must have &gt; 5 g/L absolute increase in paraprotein

          -  Registered in the Myeloma X Relapse (Intensive) Trial and received 2-4 courses of PAD
             re-induction chemotherapy according to the protocol (consolidation phase)

          -  Adequate stem cell mobilization available for transplantation defined as ≥ 2x10^6 CD34
             + cells/kg or ≥ 2x10^8 PBMC/kg including cells stored from a previous harvest
             (consolidation phase)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1 x 10^9/L

          -  Platelet count ≥ 50 x 10^9/L

          -  Creatinine clearance ≥ 30 mL/min

          -  Total bilirubin &lt; 2 times upper limit of normal (ULN)

          -  ALT or AST &lt; 2.5 times ULN

          -  History of pulmonary disease allowed provided carbon monoxide diffusion in the lungs
             (KCO/DLCO) is ≥ 50% and/or no requirement for supplementary continuous oxygen

          -  Left ventricular ejection fraction ≥ 40% by ECG or MUGA scan

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No peripheral neuropathy ≥ grade 2

          -  No known HIV or Hepatitis B or C positivity (testing is not required)

          -  No known resistance to combined bortezomib, doxorubicin hydrochloride, and
             dexamethasone therapy

          -  No known history of allergy to compounds containing boron or mannitol

          -  No other previous or concurrent malignancies except for appropriately treated
             localized epithelial skin cancer or carcinoma in situ of the cervix, or remote
             histories of other cured tumors within the past 5 years

          -  No medical or psychiatric condition which, in the opinion of the investigator,
             contraindicates the patient's participation in the study

          -  No other contra-indication to treatment that would make the patient ineligible for
             consolidation phase

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No other prior therapy for relapsed disease except for local radiotherapy, therapeutic
             plasma exchange, or ≤ 200 mg of dexamethasone

               -  Radiotherapy since prior transplantation sufficient to alleviate or control pain
                  of local invasion is permitted

          -  No hemi-body radiation since prior transplantation (consolidation phase)

          -  At least 4 weeks since prior and no concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Cook, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-125-631-4793</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-121-472-1311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-121-424-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-202-303-626</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <state>England</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1274-542-200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frenchay Hospital</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS16 1LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-970-1212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1223-245-151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Helier Hospital</name>
      <address>
        <city>Carshalton</city>
        <state>England</state>
        <zip>SM5 1AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-8296-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Oncology Centre at Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>England</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-8454-222-222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Richards Hospital</name>
      <address>
        <city>Chichester</city>
        <state>England</state>
        <zip>P019 4SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1243-788-122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <state>England</state>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1206-747-474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital</name>
      <address>
        <city>Dorchester</city>
        <state>England</state>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1305-251-150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital</name>
      <address>
        <city>Dudley</city>
        <state>England</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1384-456-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>England</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1392-411-611</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <state>England</state>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-8454-222-222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1473-712-233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-206-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-706-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-525-5980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7601-8391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7188-7188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-3299-9000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-208-672-1255</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7636-8333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-161-276-1234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-845-226-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1642-850-850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-191-233-6161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>England</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-603-286-286</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-115-969-1169</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1865-64841</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>England</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-175-277-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Berkshire Cancer Centre at Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <state>England</state>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-118-322-7878</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rotherham General Hospital</name>
      <address>
        <city>Rotherham</city>
        <state>England</state>
        <zip>S60 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1709-820-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <state>England</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1722-336-262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-114-271-1900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-23-8079-8751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-8642-6011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>England</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1823-333-444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>England</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1803-614-567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arrowe Park Hospital</name>
      <address>
        <city>Wirral</city>
        <state>England</state>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-151-678-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital Trust Incorporating Belvoir Park Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT8 8JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-2890-699-069</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-84-5456-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <state>Scotland</state>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1292-610-555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1382-660-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-141-211-2123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <state>Scotland</state>
        <zip>1V2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1463-704-000 ext. 4310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crosshouse Hospital</name>
      <address>
        <city>Kilmarnock</city>
        <state>Scotland</state>
        <zip>KA2 OBE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1563-521-133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinderfields General Hospital</name>
      <address>
        <city>Wakefield</city>
        <state>Scotland</state>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-84-4811-8110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd</name>
      <address>
        <city>Bangor</city>
        <state>Wales</state>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1248-370-007</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1745-583-910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1792-285-501</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

